Posted by Michael Wonder on 13 Jan 2018
Cour Pharmaceuticals receives FDA fast track designation for TIMP-GLIA
8 January 2018 - TIMP-GLIA is designed to enable patients to develop tolerance to gluten.
Cour Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for TIMP-GLIA, a new nanoparticle-based therapeutic being studied for the treatment of celiac disease. By encapsulating a component of wheat within a nanoparticle, Cour is developing a novel treatment which resulted in gluten tolerance in numerous animal models.
The Phase 1 program investigating the safety and tolerability of TIMP-GLIA is currently ongoing in the United States.
